These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 33309687)
1. Development and characterisation of novel, enzymatically stable oxytocin analogues with beneficial antidiabetic effects in high fat fed mice. Mohan S; McCloskey AG; McKillop AM; Flatt PR; Irwin N; Moffett RC Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129811. PubMed ID: 33309687 [TBL] [Abstract][Full Text] [Related]
2. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice. Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728 [TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes. Vasu S; Ojo OO; Moffett RC; Conlon JM; Flatt PR; Abdel-Wahab YHA Amino Acids; 2017 Oct; 49(10):1705-1717. PubMed ID: 28836148 [TBL] [Abstract][Full Text] [Related]
4. The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity and islet function and decreases plasma lipids in high-fat fed mice. Srinivasan D; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YHA Eur J Pharmacol; 2015 Oct; 764():38-47. PubMed ID: 26123844 [TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice. O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR PLoS One; 2018; 13(8):e0202350. PubMed ID: 30157220 [TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance. Tanday N; Irwin N; Flatt PR; Moffett RC Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307 [TBL] [Abstract][Full Text] [Related]
7. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice. Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015 [TBL] [Abstract][Full Text] [Related]
8. [I10W]tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice. Srinivasan DK; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YH Acta Diabetol; 2016 Apr; 53(2):303-15. PubMed ID: 26138324 [TBL] [Abstract][Full Text] [Related]
9. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion. McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide. Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155 [TBL] [Abstract][Full Text] [Related]
11. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes. Tanday N; English A; Lafferty RA; Flatt PR; Irwin N Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734 [TBL] [Abstract][Full Text] [Related]
12. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. O'Harte FP; Franklin ZJ; Irwin N Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150 [TBL] [Abstract][Full Text] [Related]
13. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice. Pathak NM; Pathak V; Lynch AM; Irwin N; Gault VA; Flatt PR Mol Cell Endocrinol; 2015 Sep; 412():95-103. PubMed ID: 26048772 [TBL] [Abstract][Full Text] [Related]
15. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes. Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087 [TBL] [Abstract][Full Text] [Related]
16. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities. Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703 [TBL] [Abstract][Full Text] [Related]
17. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice. O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054 [TBL] [Abstract][Full Text] [Related]
18. Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed mice. Mohan S; Flatt PR; Irwin N; Moffett RC Diabetes Obes Metab; 2021 Oct; 23(10):2215-2225. PubMed ID: 34105240 [TBL] [Abstract][Full Text] [Related]